Skip to content

CASI PHARMACEUTICALS, INC.: 10-Q filed 2016-05-13

What CASI PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-05-13 (fiscal Q1 2016): 21 published measures, 44 facts as tagged in accession 0001144204-16-101476.

This filing

Form
10-Q (quarterly report)
Filed
2016-05-13
Fiscal period
fiscal Q1 2016
Accession
0001144204-16-101476 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CASI PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-03-3114,524,681USD
At 2015-12-315,826,315USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-03-319,888,089USD
At 2015-12-3111,913,756USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-03-314,636,592USD
At 2015-12-31-6,087,441USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-03-3113,944,509USD
At 2015-12-315,131,114USD
At 2015-03-319,459,135USD
At 2014-12-3110,669,919USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-03-31-1,794,366USD91
2015-01-01 to 2015-03-31-1,803,353USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-03-3163,664USD91
2015-01-01 to 2015-03-311,051USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-03-31-434,272,705USD
At 2015-12-31-432,478,339USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-03-31222,824USD
At 2015-12-31218,796USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-03-31372,103USD91
2015-01-01 to 2015-03-31399,374USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-03-3114,263,683USD
At 2015-12-315,569,345USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-03-312,413,413USD
At 2015-12-311,053,564USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-03-31783,339USD
At 2015-12-31884,100USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-01-01 to 2016-03-311,018,757USD91
2015-01-01 to 2015-03-31865,037USD90

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-03-31446,516,914USD
At 2015-12-31434,099,890USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-03-3138,174USD
At 2015-12-3138,174USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-03-31158,099USD
At 2015-12-31169,464USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-03-31319,174USD
At 2015-12-31438,231USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-03-31765,075USD91
2015-01-01 to 2015-03-31924,780USD90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-03-3110,281,955USD91
2015-01-01 to 2015-03-310USD90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-03-310USD91
2015-01-01 to 2015-03-31-9USD90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-03-31-100,761USD91
2015-01-01 to 2015-03-31240,310USD90

Inspect the source

Entity
CASI PHARMACEUTICALS, INC. / CIK 0000895051
Captured
SEC response SHA-256
a5465bb63979ec441cdd2d0b7761265dc0541f5ee25dcdffded348a960f99c09

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000895051.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))